GT Healthcare in $26m series-B for Exscientia

The fresh capital will be used to scale the company's pipeline, and advance selected programmes towards clinical development, with the target of establishing an expansive portfolio of projects, both in-house and with partners by the end of 2019. In addition, Exscientia plans to further expand its business, especially in Asia.

Previous funding
Exscientia raised a $15m funding round from drug discovery specialist Evotec in September 2017.

Company
Founded in 2012 and based in Oxford, Exscientia specialises in AI-driven drug discovery. The company's platform, Centaur Chemist, enables it to move rapidly from idea generation to new drug molecules ready for clinical development.

People
GT Healthcare Capital Partners – Alan Au (managing partner). 
Exscientia – Andrew Hopkins (founder, CEO); Alex Snow (executive chair).

Advisers
Company – Rothschild & Co (corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• Venture
• United Kingdom
• Rothschild